NDP-MSH Improves Marginal Lungs During Ex Vivo Perfusion, Boosting Transplant Potential

Lung transplantation is a life-saving procedure for patients with end-stage lung disease, but donor organ shortages are a major challenge globally. Many potential donor lungs are deemed "marginal" due to injury or dysfunction, making them unsuitable for immediate transplantation. Current methods to recondition these marginal lungs during ex vivo lung perfusion (EVLP), a technique where lungs are maintained outside the body, are limited, and there's a critical need to enhance their recovery and expand the pool of transplantable organs. This study explores a novel therapeutic approach to address this gap.

The study demonstrated that NDP-MSH significantly improved key physiological parameters in the treated lungs, indicating substantial recovery. Treated lungs showed a remarkable 35% increase in oxygenation capacity (PaO2/FiO2 ratio) compared to controls (p<0.01), signifying greatly enhanced gas exchange efficiency. Furthermore, NDP-MSH effectively reduced markers of inflammation, with a 42% decrease in perfusate IL-6 levels (p<0.05) and a 2.3-fold reduction in neutrophil infiltration in lung tissue, suggesting a potent anti-inflammatory effect. Lung compliance, a crucial measure of lung elasticity and ease of inflation, improved by 20% in the NDP-MSH group compared to controls, indicating less tissue stiffness and better mechanical function. These improvements collectively suggest a substantial recovery of lung function, making these previously marginal organs potentially suitable for transplantation.